Suppr超能文献

在胱氨酸尿症患者长期服用硫普罗宁治疗期间,游离胱氨酸及硫普罗宁-半胱氨酸混合二硫化物的尿排泄情况。

Urinary excretion of free cystine and the tiopronin-cysteine-mixed disulfide during long term tiopronin treatment of cystinuria.

作者信息

Lindell A, Denneberg T, Jeppsson J O

机构信息

Department of Nephrology, University Hospital, Linköping, Sweden.

出版信息

Nephron. 1995;71(3):328-42. doi: 10.1159/000188740.

Abstract

We report the results of a biochemical evaluation of long-term treatment of cystinuria with the SH compound tiopronin (2-mercaptopropionylglycine). The effects of tiopronin were studied by monitoring the urinary excretion of free cysteine and the mixed disulfide between tiopronin and cysteine. Thirty-one patients with homozygous cystinuria were treated with tiopronin for 0.4-12 years (mean 7.8 years). The urinary concentration of free cysteine was used to adjust the tiopronin dose. In 28 of the 31 patients a mean urinary cystine concentration of less than 1,200 mumol/1(288 mg/l) was achieved with the final dose. The final daily doses of tiopronin ranged from 250 mg (1.5 mmol) to 3,000 mg (18.4 mmol; mean 1,540 mg; 9.4 mmol). In a majority of the patients the treatment reduced the 24-hour urinary free cystine excretion effectively, on average by 0.61 mumol (0.15 mg)/mg of tiopronin administered. No changes in the efficacy of tiopronin over time were observed, and the frequency of adverse effects was acceptable. To evaluate the effects of tiopronin on the metabolism of cystine we calculated the total urinary excretion of cystine as the sum of free cystine and the amount of cystine corresponding to the cysteine content of the tiopronin-cysteine disulfide. At low doses of tiopronin there was an increase in urinary excretion of the mixed disulfide as well as of total cystine. Monitoring urinary cystine concentration is necessary to achieve adequate individualized doses of tiopronin. Assessment of the mixed tiopronin-cysteine disulfide and the urinary excretion of total cystine shows that tiopronin may interfere with cystine metabolism in a more complex way than through a simple disulfide exchange reaction with urinary cystine.

摘要

我们报告了用SH化合物硫普罗宁(2-巯基丙酰甘氨酸)长期治疗胱氨酸尿症的生化评估结果。通过监测游离半胱氨酸的尿排泄量以及硫普罗宁与半胱氨酸之间的混合二硫化物,研究了硫普罗宁的作用。31例纯合子胱氨酸尿症患者接受硫普罗宁治疗0.4 - 12年(平均7.8年)。用游离半胱氨酸的尿浓度来调整硫普罗宁剂量。31例患者中有28例最终剂量时平均尿胱氨酸浓度低于1200μmol/L(288mg/L)。硫普罗宁的最终日剂量范围为250mg(1.5mmol)至3000mg(18.4mmol;平均1540mg;9.4mmol)。在大多数患者中,治疗有效降低了24小时尿游离胱氨酸排泄量,平均每服用1mg硫普罗宁降低0.61μmol(0.15mg)。未观察到硫普罗宁的疗效随时间有变化,且不良反应发生率可接受。为评估硫普罗宁对胱氨酸代谢的影响,我们将尿胱氨酸的总排泄量计算为游离胱氨酸与对应于硫普罗宁 - 半胱氨酸二硫化物中半胱氨酸含量的胱氨酸量之和。在低剂量硫普罗宁时,混合二硫化物以及总胱氨酸的尿排泄量增加。监测尿胱氨酸浓度对于获得足够的个体化硫普罗宁剂量很有必要。对硫普罗宁 - 半胱氨酸混合二硫化物和总胱氨酸尿排泄量的评估表明,硫普罗宁可能以比通过与尿胱氨酸进行简单二硫化物交换反应更复杂的方式干扰胱氨酸代谢。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验